Skip To Main Content
Aimaz Afrough on Muck Rack

Aimaz Afrough

As seen in: Nature, MDPI, Texas Medical Center, OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Aimaz Afrough’s profile

Articles by Aimaz Afrough

Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study

|
By Doris Hansen, Danai Dima, Ruta Brazauskas, Temitope Oloyede, Aimaz Afrough, Nausheen Ahmed, Larry Anderson, Rahul Banerjee, Jesus G Berdeja, Aram Bidikian, Binod Dhakal, Yvonne A. Efebera, Muhammad Faisal, Lohith Gowda, Hamza Hashmi, Abu-Sayeef Mirza, Meera Mohan, Ravi Narra, Ashley Rosko, Mark Schroeder, Taiga Nishihori, Heather Landau, Saad Usmani, Marcelo C. Pasquini, Othman S. Akhtar, Surbhi Sidana, Jakob Devos, Ajoy Dias
| Nature Verified
Abstract Ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, was approved in 2022 for heavily pretreated relapsed/refractory multiple myeloma (RRMM). This study evaluates the safety and efficacy of cilta-cel in RRMM patients reported to the Center for International Blood and Marrow Transplant Research registry between March 2022 and December 2023 who met commercial release specifications.
Open in Who Shared Issue with article?

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

|
By Andrew J. Portuguese, James Davis, Shahzad Raza, Omar Castaneda Puglianini, Ciara L Freeman, Melissa Alsina, Corbin Wright, Brandon Blue, Rachid Baz, Kenneth H Shain, Utkarsh Goel, Jack Khouri, Faiz Anwer, Hossam Ali, Oren Pasvolsky, Mahmoud R. Gaballa, Damian Mikulski, Lindsay Fogel, Eli Zolotov, Aishwarya Sannareddy, Aimaz Afrough, Larry D. Jr, Kelley Julian, Danai Dima, Rahul Banerjee, Emily Liang, Raffaella Cassano, Megan Herr Verified, Hamza Hassan, Leyla O. Shune, Jeries Kort, Shonali Midha, Omar Nadeem, Surbhi Sidana, Yi Lin, Frederick Locke, Doris Hansen, Douglas Sborov, Noa Biran, Ariel Grajales-Cruz, Hector Garcia-Pleitez
| Nature Verified
Abstract Elranatamab, a BCMA-CD3 bispecific antibody, has demonstrated robust activity in relapsed/refractory multiple myeloma (RRMM), but real-world outcomes remain poorly defined. We conducted a multicenter retrospective study of 130 patients treated with commercial elranatamab across nine U.S. academic centers. The cohort was heavily pretreated (91% triple-class refractory, 49% penta-refractory), with 49% previously exposed to BCMA-targeted therapies.
Open in Who Shared Issue with article?

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)—real world experience from the US multiple myeloma immunotherapy consortium

|
By CINDY varga, Myra Robinson, James Davis, Hamza Hashmi, Thomas Martin, Anupama Kumar, Douglas Sborov, Charlotte Wagner, Doris Hansen, Omar Castaneda Puglianini, Leyla O. Shune, Aimaz Afrough, Larry D. Jr, Binod Dhakal, Megan Herr Verified, Shambavi Richard, Alex Lieberman-Cribbin, Daniel W. Sherbenou, Peter Forsberg, Sneha Purvey, Jack Khouri, Yi Lin, Surbhi Sidana, Shonali Midha, Christopher J. Ferreri, Evgeunia Bhurtel, Mehmet Kocoglu
| Nature Verified
Abstract Prolonged cytopenias are a well-recognized complication following CAR-T therapy. Autologous SCB offers a potential strategy to promote fast hematologic recovery. We conducted a retrospective multi-institutional comparing outcomes of SCB versus supportive care alone in patients with prolonged cytopenias after CAR-T infusion. Patients were included if they received SCB within 1 year following commercial CAR-T between 6/2021 and 3/2024.
Open in Who Shared Issue with article?

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience | Blood Cancer Journal

|
By Aimaz Afrough, Utkarsh Goel, Oren Pasvolsky, Mariola Vazquez-Martinez, Christopher J. Ferreri, Rahul Banerjee, Jack Khouri, James Davis, Mahmoud R. Gaballa, Masooma Rana, Kelley Julian, Faiz Anwer, Sandra Susanibar-Adaniya, Andrew J. Portuguese, Daniel Schrum, Gurbakhash Kaur, Joseph McGuirk, Megan Herr Verified, Omar Castañeda, Shahzad Raza, Yi Lin, Shebli Atrash, Douglas Sborov, Peter M Voorhees, Shambavi Richard, Alfred Garfall, Surbhi Sidana, Doris Hansen, Alex Lieberman-Cribbin
| Nature Verified
Abstract Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated with teclistamab at 13 U.S. centers through September 2023, with follow-up to April 2024.
Open in Who Shared Issue with article?

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

|
By Aimaz Afrough
| Texas Medical Center
Abstract Despite remarkable progress in survival with the availability of novel agents, an overwhelming majority of patients with multiple myeloma (MM) have disease that relapses. Allogeneic (allo-) hematopoietic cell transplantation (HCT) is a potentially curative option for a subgroup of patients with high-risk MM. This study assessed the long-term outcome of MM patients who underwent allo-HCT while in first remission as consolidation treatment.
Open in Who Shared Issue with article?

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal

|
By Oren Pasvolsky, Lei Feng, James Davis, Aimaz Afrough, Mariola Vazquez-Martinez, Utkarsh Goel, Rahul Banerjee, Jack Khouri, Mahmoud R. Gaballa, Kelley Julian, Christopher J. Ferreri, Sandra Susanibar Adaniya, Andrew J. Portuguese, Gurbakhash Kaur, Megan Herr Verified, Chenyu Lin, Shahzad Raza, Yi Lin, Joseph McGuirk, Peter M Voorhees, Faiz Anwer, Alfred Garfall, Surbhi Sidana, Doris Hansen, Shambavi Richard, Hans C. Lee, Daniel Schrum, Shebli Atarsh
| Nature Verified
Abstract Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab.
Open in Who Shared Issue with article?

Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium - Blood Cancer Journal

|
By Aimaz Afrough, Doris Hansen, Surbhi Sidana, Lauren C. Peres, Danai Dima, Joseph McGuirk, Douglas Sborov, James Davis, Gurbakhash Kaur, Christopher J. Ferreri, Charlotte Wagner, Omar Castaneda Puglianini
| Nature Verified
Idecabtagene vicleucel (ide-cel) the first FDA-approved gene therapy for relapsed refractory multiple myeloma (RRMM). However, its administration presents challenges in logistical management, selecting bridging therapy (BT), and customizing T-cell manufacturing, a complex process spanning several weeks [1]. In the KarMMa trial, BT was allowed but limited to specific prior drug classes (e.g., dexamethasone, cyclophosphamide (Cy), daratumumab, carfilzomib, bortezomib, or pomalidomide) [2].
Open in Who Shared Issue with article?

Cancers | Free Full-Text | Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Multiple Myeloma

|
By Shebli Atrash, Barry Paul, Aimaz Afrough, Evguenia Ouchveridze
| MDPI
1. Introduction Daratumumab is a human immunoglobulin G1 kappa monoclonal antibody targeting CD38 originally approved for monotherapy treatment of relapsed refractory multiple myeloma (RRMM) in 2015. Subsequently, the addition of daratumumab to various backbones have yielded exceptional efficacy in RRMM, transplant-eligible, and transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients [1,2,3,4].
Open in Who Shared Issue with article?
Show More